The Acute Haemodynamic Effect of Nebulised Frusemide in Stable, Advanced Heart Failure

Phillip J. Newton, Patricia M Davidson, Henry Krum, Richard Ollerton, Peter Macdonald

Research output: Contribution to journalArticle

Abstract

Purpose: To assess the acute haemodynamic effects of nebulised frusemide in a stable advanced heart failure population. Procedure: In this randomised, double blind, placebo controlled trial, people with stable, advanced heart failure undergoing right heart catheterisation were randomised to receive either 40. mg (4. ml) of nebulised frusemide or 4. ml of normal saline. Following inhalation of the study medication, subjects' pulmonary pressures were recorded every 15. min for 1. h. Findings: There were no significant changes in the weighted average time course data of the subjects (n= 32) in either group over the study period, in particular no differences were observed in haemodynamic parameters between the two groups. Weighted average pulmonary capillary wedge pressure after 60. min in the frusemide group was 22.5 (SD 6.5) mmHg (n= 14) compared to the placebo group's 24.0 (SD 7.3) mmHg (n= 18), p= 0.55. The frusemide group had a significantly greater change in the median volume of urine in the bladder over the study period (186. ml IQR 137.8-260.8) compared to the placebo group (76. ml IQR 39.0-148.0) p= 0.02. Conclusion: This study showed that nebulised frusemide had no significant clinical effect on the haemodynamic characteristics of the subjects.

Original languageEnglish (US)
Pages (from-to)260-266
Number of pages7
JournalHeart Lung and Circulation
Volume21
Issue number5
DOIs
StatePublished - May 2012
Externally publishedYes

Fingerprint

Furosemide
Heart Failure
Hemodynamics
Placebos
Pulmonary Wedge Pressure
Cardiac Catheterization
Inhalation
Urinary Bladder
Urine
Pressure
Lung
Population

Keywords

  • Frusemide
  • Haemodynamics
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine

Cite this

The Acute Haemodynamic Effect of Nebulised Frusemide in Stable, Advanced Heart Failure. / Newton, Phillip J.; Davidson, Patricia M; Krum, Henry; Ollerton, Richard; Macdonald, Peter.

In: Heart Lung and Circulation, Vol. 21, No. 5, 05.2012, p. 260-266.

Research output: Contribution to journalArticle

Newton, Phillip J. ; Davidson, Patricia M ; Krum, Henry ; Ollerton, Richard ; Macdonald, Peter. / The Acute Haemodynamic Effect of Nebulised Frusemide in Stable, Advanced Heart Failure. In: Heart Lung and Circulation. 2012 ; Vol. 21, No. 5. pp. 260-266.
@article{3e639c51e87a42bda91250275664db1a,
title = "The Acute Haemodynamic Effect of Nebulised Frusemide in Stable, Advanced Heart Failure",
abstract = "Purpose: To assess the acute haemodynamic effects of nebulised frusemide in a stable advanced heart failure population. Procedure: In this randomised, double blind, placebo controlled trial, people with stable, advanced heart failure undergoing right heart catheterisation were randomised to receive either 40. mg (4. ml) of nebulised frusemide or 4. ml of normal saline. Following inhalation of the study medication, subjects' pulmonary pressures were recorded every 15. min for 1. h. Findings: There were no significant changes in the weighted average time course data of the subjects (n= 32) in either group over the study period, in particular no differences were observed in haemodynamic parameters between the two groups. Weighted average pulmonary capillary wedge pressure after 60. min in the frusemide group was 22.5 (SD 6.5) mmHg (n= 14) compared to the placebo group's 24.0 (SD 7.3) mmHg (n= 18), p= 0.55. The frusemide group had a significantly greater change in the median volume of urine in the bladder over the study period (186. ml IQR 137.8-260.8) compared to the placebo group (76. ml IQR 39.0-148.0) p= 0.02. Conclusion: This study showed that nebulised frusemide had no significant clinical effect on the haemodynamic characteristics of the subjects.",
keywords = "Frusemide, Haemodynamics, Heart failure",
author = "Newton, {Phillip J.} and Davidson, {Patricia M} and Henry Krum and Richard Ollerton and Peter Macdonald",
year = "2012",
month = "5",
doi = "10.1016/j.hlc.2012.03.002",
language = "English (US)",
volume = "21",
pages = "260--266",
journal = "Heart Lung and Circulation",
issn = "1443-9506",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The Acute Haemodynamic Effect of Nebulised Frusemide in Stable, Advanced Heart Failure

AU - Newton, Phillip J.

AU - Davidson, Patricia M

AU - Krum, Henry

AU - Ollerton, Richard

AU - Macdonald, Peter

PY - 2012/5

Y1 - 2012/5

N2 - Purpose: To assess the acute haemodynamic effects of nebulised frusemide in a stable advanced heart failure population. Procedure: In this randomised, double blind, placebo controlled trial, people with stable, advanced heart failure undergoing right heart catheterisation were randomised to receive either 40. mg (4. ml) of nebulised frusemide or 4. ml of normal saline. Following inhalation of the study medication, subjects' pulmonary pressures were recorded every 15. min for 1. h. Findings: There were no significant changes in the weighted average time course data of the subjects (n= 32) in either group over the study period, in particular no differences were observed in haemodynamic parameters between the two groups. Weighted average pulmonary capillary wedge pressure after 60. min in the frusemide group was 22.5 (SD 6.5) mmHg (n= 14) compared to the placebo group's 24.0 (SD 7.3) mmHg (n= 18), p= 0.55. The frusemide group had a significantly greater change in the median volume of urine in the bladder over the study period (186. ml IQR 137.8-260.8) compared to the placebo group (76. ml IQR 39.0-148.0) p= 0.02. Conclusion: This study showed that nebulised frusemide had no significant clinical effect on the haemodynamic characteristics of the subjects.

AB - Purpose: To assess the acute haemodynamic effects of nebulised frusemide in a stable advanced heart failure population. Procedure: In this randomised, double blind, placebo controlled trial, people with stable, advanced heart failure undergoing right heart catheterisation were randomised to receive either 40. mg (4. ml) of nebulised frusemide or 4. ml of normal saline. Following inhalation of the study medication, subjects' pulmonary pressures were recorded every 15. min for 1. h. Findings: There were no significant changes in the weighted average time course data of the subjects (n= 32) in either group over the study period, in particular no differences were observed in haemodynamic parameters between the two groups. Weighted average pulmonary capillary wedge pressure after 60. min in the frusemide group was 22.5 (SD 6.5) mmHg (n= 14) compared to the placebo group's 24.0 (SD 7.3) mmHg (n= 18), p= 0.55. The frusemide group had a significantly greater change in the median volume of urine in the bladder over the study period (186. ml IQR 137.8-260.8) compared to the placebo group (76. ml IQR 39.0-148.0) p= 0.02. Conclusion: This study showed that nebulised frusemide had no significant clinical effect on the haemodynamic characteristics of the subjects.

KW - Frusemide

KW - Haemodynamics

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=84861201429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861201429&partnerID=8YFLogxK

U2 - 10.1016/j.hlc.2012.03.002

DO - 10.1016/j.hlc.2012.03.002

M3 - Article

C2 - 22503786

AN - SCOPUS:84861201429

VL - 21

SP - 260

EP - 266

JO - Heart Lung and Circulation

JF - Heart Lung and Circulation

SN - 1443-9506

IS - 5

ER -